Treatment priorities of people living with food allergies are at the core of a special initiative called the “Food Allergy Collaborative.”

AAFA and several other patient advocacy groups joined together to form the Food Allergy Collaborative ^[3] – an alliance to advance patient-centered research and care.  As part of the collaboration, we hosted an externally-led patient-focused drug development (PFDD) meeting on September 9, 2021 in the Washington, D.C. area. It provided the food allergy community an opportunity to speak directly to Food and Drug Administration (FDA) staff, representatives of pharmaceutical and medical device companies, and other key stakeholders. This opportunity allows people with food allergies to inform and shape development of drugs and medical devices designed to treat food allergy in children and adults.

The resulting Voice of the Patient Report for Food Allergies will inform new treatment strategies, effectively engage families in drug development, and improve health outcomes. This initiative was the first of its kind for food allergy. Your voice and perspectives are essential for us to elevate the needs of individuals and families managing food allergies.